UroGen Pharma (NASDAQ:URGN) Downgraded to Sell at Zacks Investment Research

UroGen Pharma (NASDAQ:URGN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product […]

Related Keywords

Israel ,Raanana ,Hamerkaz ,Urogen Pharma ,Rice Hall James Associates ,Berenberg Bank ,Zacks Investment Research ,Urogen Pharma Ltd ,Investment Management ,Denali Advisors ,Goldman Sachs Group ,Barclays Plc ,Get Rating ,Gen Pharma ,Hall James ,Gen Pharma Ltd ,Nasdaq Urgn ,Burgn ,Medical ,Downgrade ,